Piper Jaffray analyst Danielle Brill said her survey of 40 doctors that treat sickle cell disease found that the initial demand for Oxbryta appears "even more robust" than she anticipated, with a total of 211 Oxbryta prescriptions written since launch just over two weeks ago and the treatment distributed to 105 out of those 211 patients. 100% of the 40 surveyed doctors plan to prescribe Oxbryta in the next three months, added Brill, who said the survey findings reaffirm her view that Oxbryta will be a commercial success. She keeps an Overweight rating on Global Blood Therapeutics shares with a $120 price target.